BioCryst Pharmaceuticals | BCRX - 债务



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.97B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


债务 更改 日
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Chugai Pharma JPY 14.11B 1.93B 2022-12
Daiichi Sankyo JPY 300.48B 99.34B 2026-03
DBV Technologies USD 6.1M 2.49M 2026-03
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 22.17B 2.76B 2026-03
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
Incyte USD 38.27M 1.16M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novavax USD 233.31M 4.23M 2024-09
PTC Therapeutics USD 286.94M 2.42B 2026-03
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.98B 8.9M 2026-06